PMS11 INFLIXIMAB COSTS AND REASONS FOR TREATMENT DISCONTINUATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TREATMENT IN U.S. HOSPITALS: 2012-2015

Autor:	A. Kartashov, C. Arsever, D. Wu, N. Rosenthal, D. Baumer
Rok vydání:	2019
Předmět:	medicine.medical_specialty business.industry Health Policy Internal medicine Rheumatoid arthritis Public Health Environmental and Occupational Health medicine medicine.disease business Infliximab medicine.drug Discontinuation
Zdroj:	Value in Health. 22:S240
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.04.1122
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c0404ee97e2a324e147c2d28a5eb358a https://doi.org/10.1016/j.jval.2019.04.1122 Zobrazit plný text záznamu Full Text from ScienceDirect